Prostate News Archive
28-Feb-2007
New Class Of Targeted Cancer Drugs Shows Promise In Slowing Progression Of Recurrent Prostate Cancer (Science Daily)
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. Prostate Cancer: Radiation Not Best (WebMD)
Men who receive external radiation therapy for prostate cancer are more likely to die over the next five years than those treated with radioactive seed implants or surgery to remove the prostate, a new study suggests. Rating Radiation For Prostate Cancer (CBS News)
Men who receive external radiation therapy for prostate cancer are more likely to die over the subsequent five years than those treated with radioactive seed implants or surgery to remove the prostate, a new study suggests. Scientists tout new prostate cancer test (AP via Yahoo! News)
Oregon scientists say a simple test can identify men at high risk of life-threatening prostate cancer even after a biopsy finds no signs of it. The key, researchers say, is "PSA density," which compares the size of a man's prostate with his levels of a cancer-related protein called prostate-specific antigen. Some prostate cancer treatments better than others (Reuters via Yahoo! News)
An analysis of men with early prostate cancer treated at the Cleveland Clinic found that those treated with external beam radiation therapy had poorer overall survival than those treated with radioactive seed implants (brachytherapy) or by surgical removal of the prostate (radical prostatectomy).
Back to Prostate News Archive
